These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. New drugs and regimens for treatment of TB. Leibert E; Rom WN Expert Rev Anti Infect Ther; 2010 Jul; 8(7):801-13. PubMed ID: 20586565 [TBL] [Abstract][Full Text] [Related]
3. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215 [TBL] [Abstract][Full Text] [Related]
4. [Present and future in the use of anti-tubercular drugs]. Didilescu C; Craiova UM Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558 [TBL] [Abstract][Full Text] [Related]
7. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149 [TBL] [Abstract][Full Text] [Related]
8. New antituberculous drugs in development. Lalloo UG; Ambaram A Curr HIV/AIDS Rep; 2010 Aug; 7(3):143-51. PubMed ID: 20559756 [TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
10. Drug-resistant tuberculosis: what are the treatment options? Albanna AS; Menzies D Drugs; 2011 May; 71(7):815-25. PubMed ID: 21568360 [TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolones for the treatment of pulmonary tuberculosis. Moadebi S; Harder CK; Fitzgerald MJ; Elwood KR; Marra F Drugs; 2007; 67(14):2077-99. PubMed ID: 17883288 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022 [TBL] [Abstract][Full Text] [Related]
13. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Regazzi M; Carvalho AC; Villani P; Matteelli A Clin Pharmacokinet; 2014 Jun; 53(6):489-507. PubMed ID: 24777631 [TBL] [Abstract][Full Text] [Related]
14. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis. Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570 [TBL] [Abstract][Full Text] [Related]
15. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. API Consensus Expert Committee J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350 [TBL] [Abstract][Full Text] [Related]
16. Current development and future prospects in chemotherapy of tuberculosis. Nuermberger EL; Spigelman MK; Yew WW Respirology; 2010 Jul; 15(5):764-78. PubMed ID: 20546189 [TBL] [Abstract][Full Text] [Related]